We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
Read MoreHide Full Article
Fate Therapeutics, Inc. (FATE - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $17.28–$29.46 in the past one-month time frame, witnessed a sharp increase on Friday.
The stock gained after the company reported that it has signed a global collaboration and option agreement with Janssen Biotech, a subsidiary of pharma giant J&J.
The Zacks Consensus Estimate for the company has moved higher over the past few weeks for the current quarter, suggesting that more solid trading could be ahead for Fate Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Fate Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
Fate Therapeutics, Inc. (FATE - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $17.28–$29.46 in the past one-month time frame, witnessed a sharp increase on Friday.
The stock gained after the company reported that it has signed a global collaboration and option agreement with Janssen Biotech, a subsidiary of pharma giant J&J.
The Zacks Consensus Estimate for the company has moved higher over the past few weeks for the current quarter, suggesting that more solid trading could be ahead for Fate Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Fate Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Fate Therapeutics, Inc. Price
Fate Therapeutics, Inc. price | Fate Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry Alector, Inc. (ALEC - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>